Holen Sie sich die Stockscreener-App
32.02
2.94%
-0.97
Handel nachbörslich:
32.02
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
Form 4 Pharvaris N.V. For: 26 September By Investing.com - Investing.com Nigeria
Form 4 Pharvaris N.V. For: 26 September - Investing.com India
Trade Alert: Independent & Non-Executive Vice Chairman Of Pharvaris Hans J. G. C. Schikan Has Sold Stock - webull.com
A Pharvaris (PHVS) director proposes selling shares valued at $395,524. - Stock Titan
Form 4 Pharvaris N.V. For: 23 September - Investing.com India
Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com Nigeria
(PHVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Planned $7M Pharvaris (NASDAQ: PHVS) stock sale disclosed for founder shares - Stock Titan
After $7M stock sale, Pharvaris (NASDAQ: PHVS) director plans more - Stock Titan
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade - Eastern Progress
Form 4 Pharvaris N.V. For: 22 September By Investing.com - Investing.com India
Pharvaris (PHVS) Insider Trading Activity 2026 - MarketBeat
Pharvaris (NASDAQ: PHVS) officer plans Rule 144 sale of 6,000 shares - Stock Titan
Pharvaris (PHVS) CEO buys 300,000 shares in rights exercise - Stock Titan
Pharvaris Chief Early Development Anne Lesage disposes of USD 765,466 in common shares - Bitget
Pharvaris N.V. (PHVS) stock price, news, quote and history - Yahoo Finance Australia
Glassman Robert Executes Option Exercise and Sells 8,667 Pharvaris Shares on September 15, 2026 - Kalkine Media
Pharvaris N.V. (PHVS) Stock Analysis: Biotech Innovator With A 53.58% Potential Upside - DirectorsTalk Interviews
Pharvaris (NASDAQ: PHVS) officer to sell 100,000 shares under Rule 144 - Stock Titan
Shareholder at Pharvaris (NASDAQ: PHVS) plans multi-million-dollar stock sale - Stock Titan
Pharvaris (NASDAQ: PHVS) lines up $10.5M sale of founder stock - Stock Titan
Pharvaris (NASDAQ: PHVS) director plans nearly $2M stock sale in 2026 - Stock Titan
Founder shares in Pharvaris (NASDAQ: PHVS) set for $765K planned sale - Stock Titan
Pharvaris (NASDAQ: PHVS) director lines up new stock sale after recent trades - Stock Titan
Pharvaris N.V. (PHVS) exec sells 46,400 shares in cashless trade - Stock Titan
Souverijns Wim Executes Option Exercises and Sells 26,090 Pharvaris Shares - Kalkine Media
Pharvaris N.V. (PHVS) Edges Higher as Shares Test Resistance Near $40Strangle Setup - careplusvn.com
Pharvaris at H.C. Wainwright conference: dual HAE push gains pace By Investing.com - Investing.com Nigeria
Pharvaris at H.C. Wainwright conference: dual HAE push gains pace - Investing.com
Officer at Pharvaris (NASDAQ: PHVS) plans potential $1.77M stock sale - Stock Titan
Pharvaris (NASDAQ: PHVS) CEO sells 2,291 shares in 10b5-1 plan trade - Stock Titan
PHVS Stock Rises 10% in a Month: What Is Driving the Rally? - Eastern Progress
Pharvaris at Morgan Stanley conference: oral HAE drug nears launch By Investing.com - Investing.com Nigeria
Pharvaris at Morgan Stanley conference: oral HAE drug nears launch - Investing.com
Pharvaris (NASDAQ: PHVS) exec files to sell shares from vested stock and options - Stock Titan
2,291 Pharvaris (Nasdaq: PHVS) shares set for resale - Stock Titan
Cantor Fitzgerald reiterates Pharvaris stock rating after trial data By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Pharvaris stock rating after trial data - Investing.com
(PHVS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Pharvaris Soars on Breakthrough Trial Win and Lofty Targets - TipRanks
Pharvaris Director Robert Glassman Executes 8,000-Share Sale via Rule 10b5-1 Plan - Kalkine Media
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win? - Yahoo Finance
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2026-09-10 - Seeking Alpha
Pharvaris (NASDAQ: PHVS) officer to sell 30,000 shares in September 2026 - Stock Titan
Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum By Investing.com - Investing.com India
Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum - investing.com
PHVS Maintained by Guggenheim -- Price Target Raised to $44.00 - GuruFocus
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com Nigeria
Guggenheim raises Pharvaris stock price target on trial results - Investing.com
Pharvaris at Wells Fargo conference: oral HAE drug gains ground - Investing.com
Pharvaris at Wells Fargo conference: oral HAE drug gains ground By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Wells Fargo raises Pharvaris stock price target on strong trial data - Investing.com Nigeria
Oppenheimer raises Pharvaris stock price target on trial results By Investing.com - Investing.com Australia
Pharvaris stock gets $60 target at H.C. Wainwright on trial data - Investing.com Nigeria
Pharvaris (NASDAQ: PHVS) director plans to sell shares from option exercise - Stock Titan
PHVS Maintained by Morgan Stanley -- Price Target Raised to $62. - GuruFocus
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win - Seeking Alpha
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):